<p>, /PRNewswire/ -- Frontier Biotechnologies Inc.（以下简称 “Frontier Biotech” 或 “公司”）与全球生物制药公司 GSK 签署了独家许可协议。根据协议条款，GSK 将获得开发、制造和商业化 Frontier Biotech 的两款小干扰 RNA（siRNA）管线产品的全球独家权利，其中一款目前处于临床试验新药（IND）阶段，另一款为临床前候选药物。</p>
<p>该协议突显了公司在早期 siRNA 药物发现和开发方面的专业知识，并标志着推进其全球发展战略的重要里程碑。</p>
<p>根据协议，公司将获得 4000 万美元的预付款，以及在两个项目中基于成功的开发、监管和商业里程碑的总计高达 9.63 亿美元的资金，以及全球净销售的分级版税。</p>
<p>公司将负责这两项研究资产的初步推进，其中一项资产将在中国进行 I 期临床试验，另一项则完成 IND 启用活动。GSK 将负责所有后续的全球临床开发、监管提交和商业化活动。</p>
<p>Frontier Biotech 的董事长兼首席执行官谢东博士表示：</p>
<p>“我们很高兴与全球生物制药公司 GSK 建立协议。这反映了我们研发能力的日益认可。该协议将通过深化国际合作、加速管线价值转化，并有可能实现商业化，为 Frontier Biotech 奠定坚实的基础。”</p>
<p>近年来，siRNA 疗法等寡核苷酸已成为全球制药行业的重要发展机会。siRNA 疗法通过实现对传统药物开发的三大局限的精准基因沉默，提供持久且高度特异的疗效，并提供适用于广泛疾病的多功能平台，解决了传统药物开发的三大局限。目前，siRNA 药物开发正在加速从罕见疾病扩展到心血管和脑血管疾病及代谢紊乱等常见慢性疾病领域，展现出巨大的市场潜力。</p>
<p>GSK 的呼吸、免疫与炎症研发全球高级副总裁 Kaivan Khavandi 表示：“该协议进一步增强了我们的免疫学管线，增加了两种潜在的首创寡核苷酸疗法，有望改善多种肾脏疾病患者的治疗效果。这些资产与我们对平台技术和炎症驱动疾病的战略重点高度契合，我们期待与 Frontier Biotech 合作，推动它们的开发。”</p>
<p>关于 GSK：</p>
<p>GSK 是一家全球生物制药公司，旨在将科学、技术和人才结合起来，共同应对疾病。了解更多信息，请访问 www.gsk.com。</p>
<p>关于 Frontier Biotech：</p>
<p>Frontier Biotechnologies Inc.（“Frontier Biotech”）是一家基于研究、处于商业阶段的上市生物制药公司，致力于创新药物的发现、开发、制造和商业化。该公司在上海证券交易所上市。Frontier Biotech 开发了中国首个新型抗 HIV 药物 Aikening，也称为 Albuvirtide，这是全球首个长效注射型 HIV 融合抑制剂。我们建立了一个基于科学的商业团队，在中国和 5 个新兴市场推广 Aikening，覆盖广泛的医院和 DTP 药房，并成功将 Aikening 纳入中国国家医保药品目录和指南。我们致力于开发创新药物，专注于 siRNA，已在抗病毒、骨质疏松、代谢疾病和高脂血症等多个开发阶段建立了丰富的管线。</p>
<p>媒体联系：</p>
<p>Di Chen [email protected] / [email protected]</p>
<p>来源 Frontier Biotechnologies Inc.</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjI0Jk5ld3NJdGVtSWQ9Q045NDMxNiZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMjQwNTU1UFJfTkVXU19VU1BSX19fX19DTjk0MzE2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjI0Jk5ld3NJdGVtSWQ9Q045NDMxNiZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMjQwNTU1UFJfTkVXU19VU1BSX19fX19DTjk0MzE2"/></p>

基因改革 ETF - ARK

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

<p>Frontier Biotechnologies Inc. 与葛兰素史克（GSK）签署了一项独家许可协议，涉及两个小干扰 RNA（siRNA）产品。GSK 将支付 4000 万美元的预付款，并可能支付高达 9.63 亿美元的里程碑款项。Frontier Biotech 将在中国推进一款产品的 I 期临床试验，而 GSK 将负责全球开发和商业化。这一合作关系增强了 Frontier 的研发能力，并与 GSK 在肾脏疾病创新疗法方面的重点相一致。该协议标志着 Frontier 全球战略的重要一步，以及 siRNA 疗法在治疗各种疾病中日益增长的潜力</p>

<p>, /PRNewswire/ -- Frontier Biotechnologies Inc. (hereinafter referred to as &#34;Frontier Biotech&#34; or &#34;the Company&#34;) has entered into an exclusive licensing agreement with GSK, a global biopharma company. Under the terms of the agreement, GSK will obtain exclusive worldwide rights to develop, manufacture, and commercialize two of Frontier Biotech's Small Interfering RNA (siRNA) pipeline products, one of which is currently at Investigational New Drug (IND) stage and the other is a preclinical candidate.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Frontier Biotechnologies Inc.（以下简称 “Frontier Biotech” 或 “公司”）与全球生物制药公司 GSK 签署了独家许可协议。根据协议条款，GSK 将获得开发、制造和商业化 Frontier Biotech 的两款小干扰 RNA（siRNA）管线产品的全球独家权利，其中一款目前处于临床试验新药（IND）阶段，另一款为临床前候选药物。</p>
</div><p>This agreement highlights the Company's expertise in early-stage siRNA drug discovery and development, and marks a significant milestone in advancing its global development strategy.</p>
<div class="lb-trans"><p>该协议突显了公司在早期 siRNA 药物发现和开发方面的专业知识，并标志着推进其全球发展战略的重要里程碑。</p>
</div><p>Under the agreement, the Company will receive $40 million upfront and up to $963 million in success-based development, regulatory, and commercial milestones in total across the two programs, as well as tiered royalties on net sales worldwide.</p>
<div class="lb-trans"><p>根据协议，公司将获得 4000 万美元的预付款，以及在两个项目中基于成功的开发、监管和商业里程碑的总计高达 9.63 亿美元的资金，以及全球净销售的分级版税。</p>
</div><p>The Company will be responsible for the initial advancement of the two investigational assets, taking one asset through the Phase I clinical trial in China, and completing IND enabling activities with the other. GSK will be responsible for all subsequent global clinical development, regulatory submissions, and commercialization activities.</p>
<div class="lb-trans"><p>公司将负责这两项研究资产的初步推进，其中一项资产将在中国进行 I 期临床试验，另一项则完成 IND 启用活动。GSK 将负责所有后续的全球临床开发、监管提交和商业化活动。</p>
</div><p>Dr. Dong Xie, Chairman and CEO of Frontier Biotech, stated:</p>
<div class="lb-trans"><p>Frontier Biotech 的董事长兼首席执行官谢东博士表示：</p>
</div><p>&#34;We are excited to establish the agreement with GSK, a global biopharma company. It reflects the growing recognition of our R&amp;D capabilities. This agreement will solidify a robust foundation for Frontier Biotech by deepening international collaborations, accelerating pipeline value conversion, and potentially achieving commercialization.&#34;</p>
<div class="lb-trans"><p>“我们很高兴与全球生物制药公司 GSK 建立协议。这反映了我们研发能力的日益认可。该协议将通过深化国际合作、加速管线价值转化，并有可能实现商业化，为 Frontier Biotech 奠定坚实的基础。”</p>
</div><p>Oligonucleotides such as siRNA therapies have emerged as a major development opportunity in the global pharmaceutical sector in recent years. siRNA therapies address three limitations of traditional drug development by enabling precise gene silencing of previously undruggable targets, delivering durable and highly specific efficacy, and providing a versatile platform applicable across a broad range of diseases. Currently, siRNA drug development is accelerating its expansion from rare diseases into common chronic disease areas such as cardiovascular and cerebrovascular diseases and metabolic disorders, demonstrating great market potential.</p>
<div class="lb-trans"><p>近年来，siRNA 疗法等寡核苷酸已成为全球制药行业的重要发展机会。siRNA 疗法通过实现对传统药物开发的三大局限的精准基因沉默，提供持久且高度特异的疗效，并提供适用于广泛疾病的多功能平台，解决了传统药物开发的三大局限。目前，siRNA 药物开发正在加速从罕见疾病扩展到心血管和脑血管疾病及代谢紊乱等常见慢性疾病领域，展现出巨大的市场潜力。</p>
</div><p>Kaivan Khavandi, SVP &amp; Global Head, Respiratory, Immunology &amp; Inflammation R&amp;D, GSK said: &#34;This agreement further strengthens our immunology pipeline, adding two potential first-in-class oligonucleotide therapies with significant opportunity to improve patient outcomes across multiple kidney diseases. These assets are well-aligned with our strategic focus on platform technologies and inflammatory-driven disease, and we look forward to working with Frontier Biotech to progress them through development.&#34;</p>
<div class="lb-trans"><p>GSK 的呼吸、免疫与炎症研发全球高级副总裁 Kaivan Khavandi 表示：“该协议进一步增强了我们的免疫学管线，增加了两种潜在的首创寡核苷酸疗法，有望改善多种肾脏疾病患者的治疗效果。这些资产与我们对平台技术和炎症驱动疾病的战略重点高度契合，我们期待与 Frontier Biotech 合作，推动它们的开发。”</p>
</div><p>About GSK:</p>
<div class="lb-trans"><p>关于 GSK：</p>
</div><p>GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.</p>
<div class="lb-trans"><p>GSK 是一家全球生物制药公司，旨在将科学、技术和人才结合起来，共同应对疾病。了解更多信息，请访问 www.gsk.com。</p>
</div><p>About Frontier Biotech:</p>
<div class="lb-trans"><p>关于 Frontier Biotech：</p>
</div><p>Frontier Biotechnologies Inc. (&#34;Frontier Biotech&#34;) is a research-based, commercial-stage, publicly-traded biopharma company dedicated in the discovery, development, manufacture and commercialization of innovative medicines. The company is publicly traded in Shanghai Stock Exchange. Frontier Biotech has developed China's first new anti-HIV drug called Aikening, aka Albuvirtide, which is also the first long-acting injectable HIV fusion inhibitor in the world. We have built a science-based commercial team to promote Aikening in China and 5 emerging markets, with broad coverage of hospitals and DTP pharmacies, track record in getting Aikening into Chinese National Reimbursement Drug List and Guidelines. Dedicated to developing innovative medicine and focusing on siRNA, we have built a rich pipeline at various development stages in antiviral, osteoporosis, metabolic diseases, and hyperlipidemia.</p>
<div class="lb-trans"><p>Frontier Biotechnologies Inc.（“Frontier Biotech”）是一家基于研究、处于商业阶段的上市生物制药公司，致力于创新药物的发现、开发、制造和商业化。该公司在上海证券交易所上市。Frontier Biotech 开发了中国首个新型抗 HIV 药物 Aikening，也称为 Albuvirtide，这是全球首个长效注射型 HIV 融合抑制剂。我们建立了一个基于科学的商业团队，在中国和 5 个新兴市场推广 Aikening，覆盖广泛的医院和 DTP 药房，并成功将 Aikening 纳入中国国家医保药品目录和指南。我们致力于开发创新药物，专注于 siRNA，已在抗病毒、骨质疏松、代谢疾病和高脂血症等多个开发阶段建立了丰富的管线。</p>
</div><p>Media Contact:</p>
<div class="lb-trans"><p>媒体联系：</p>
</div><p>Di Chen [email protected] / [email protected]</p>
<div class="lb-trans"><p>Di Chen [email protected] / [email protected]</p>
</div><p>SOURCE Frontier Biotechnologies Inc.</p>
<div class="lb-trans"><p>来源 Frontier Biotechnologies Inc.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjI0Jk5ld3NJdGVtSWQ9Q045NDMxNiZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMjQwNTU1UFJfTkVXU19VU1BSX19fX19DTjk0MzE2" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN94316&amp;Transmission_Id=202602240555PR_NEWS_USPR_____CN94316&amp;DateId=20260224"/></p>

05:55 ETFrontier Biotech and GSK Enter Global Exclusive Licensing Agreement for Small Interfering RNA Therapeutics

prnewswire

2 倍做多纳斯达克生物技术 ETF - ProShares

美国制药 ETF - iShares

医药突破 ETF - ALPS

葛兰素史克

医疗业 ETF - Vanguard

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

标普生物技术 3 倍做空 - Direxion

Invesco Nasdaq Biotechnology ETF

医疗业 ETF - SPDR

05:55 ETFrontier Biotech 与葛兰素史克达成小干扰 RNA 治疗药物的全球独家许可协议